ReviewCancers2019
Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.Cancer medicine · 2025Pooled it
- Circulating Biomarkers of Thyroid Cancer: An Appraisal.Journal of clinical medicine · 2025Review
- Deciphering molecular pathways driving cancer invasion and metastasis: advances and therapeutic prospects.Frontiers in oncology · 2025Review
- Innovative aspects and applications of single cell technology for different diseases.American journal of cancer research · 2024Review
- Review
- Review
- Circulating Tumor Cells as a Promising Tool for Early Detection of Hepatocellular Carcinoma.Cells · 2023Review
- Single-Cell Analysis in theGenes · 2023Review
- Single-cell analysis technologies for cancer research: from tumor-specific single cell discovery to cancer therapy.Frontiers in genetics · 2023Review
- Isolation of TTF-1 Positive Circulating Tumor Cells for Single-Cell Sequencing by Using an Automatic Platform Based on Microfluidic Devices.International journal of molecular sciences · 2022Article
- Transcriptional Heterogeneity of Cellular Senescence in Cancer.Molecules and cells · 2022Review
- Circulating tumor cell isolation for cancer diagnosis and prognosis.EBioMedicine · 2022Review
- Article
- Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer.Frontiers in oncology · 2022Review
- Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.International journal of molecular sciences · 2021Review
- Application and prospects of single cell sequencing in tumors.Biomarker research · 2021Review
- The combination of computed tomography features and circulating tumor cells increases the surgical prediction of visceral pleural invasion in clinical T1N0M0 lung adenocarcinoma.Translational lung cancer research · 2021Article
- Microfluidics applications for high-throughput single cell sequencing.Journal of nanobiotechnology · 2021Review
- Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue.Biomedicines · 2021Review
- Distinct mRNAs in Cancer Extracellular Vesicles Activate Angiogenesis and Alter Transcriptome of Vascular Endothelial Cells.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Unlike bulk-cell analysis, single-cell approaches have the advantage of assessing cellular heterogeneity that governs key aspects of tumor biology. Yet, their applications to circulating tumor cells (CTCs) are relatively limited, due mainly to the technical challenges resulting from extreme rarity of CTCs. Nevertheless, recent advances in microfluidics and immunoaffinity enrichment technologies along with sequencing platforms have fueled studies aiming to enrich, isolate, and sequence whole genomes of CTCs with high fidelity across various malignancies. Here, we review recent single-cell CTC (scCTC) sequencing efforts, and the integrated workflows, that have successfully characterized patient-derived CTCs. We examine how these studies uncover DNA alterations occurring at multiple molecular levels ranging from point mutations to chromosomal rearrangements from a single CTC, and discuss their cellular heterogeneity and clinical consequences. Finally, we highlight emerging strategies to address key challenges currently limiting the translation of these findings to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.